Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2020

01-04-2020 | Breast Cancer | Epidemiology

Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990–2017

Authors: Zhilin Chen, Lu Xu, Wenjie Shi, Fanyu Zeng, Rui Zhuo, Xinbao Hao, Pingming Fan

Published in: Breast Cancer Research and Treatment | Issue 2/2020

Login to get access

Abstract

Purpose

Breast cancer is a major public health concern worldwide and shows significant heterogeneity between male and female. Knowing the global incidence landscape in both sexes is critical for the breast cancer prevention and the reduction in disease burden.

Methods

We retrieved the incidence data of breast cancer in both sexes from the Global Burden of Disease 2017 database. Average annual percentage change was used to quantify the temporal trends of breast cancer incidence.

Results

Between 1990 and 2017, the number of newly diagnosed female breast cancer (FBC) cases increased from 870.2 thousand to 1937.6 thousand, with the age-standardized incidence rate (ASR) significantly increased from 39.2/100,000 to 45.9/100,000. A total of 166 countries experienced a significant increase in FBC-ASR. The most pronounced increase was mainly found in developing countries. The decrease was mostly detected in several developed countries, such as the USA and the UK. Male breast cancer (MBC) is a rare carcinoma and has no evident cluster across the world. Worldwide, the number of newly diagnosed MBC cases increased from 8.5 thousand in 1990 to 23.1 thousand in 2017, with the ASR significantly increased from 0.46/100,000 to 0.61/100,000. A total of 123 countries showed a significant increasing trend in MBC-ASR.

Conclusions

Breast cancer incidence rates are increasing in most countries in both sexes, although the epidemiological features were not completely shared between FBC and MBC. More emphases should be placed on breast cancer primary prevention and the prevention strategies might need to be tailored for both FBC and MBC.
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424PubMed Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424PubMed
3.
go back to reference Abubakar M, Sung H, Bcr D et al (2018) Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population. Breast Cancer Res 20(1):114CrossRefPubMedPubMedCentral Abubakar M, Sung H, Bcr D et al (2018) Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population. Breast Cancer Res 20(1):114CrossRefPubMedPubMedCentral
4.
go back to reference Engmann NJ, Golmakani MK, Miglioretti DL et al (2017) Population-attributable risk proportion of clinical risk factors for breast cancer. JAMA Oncol 3(9):1228–1236CrossRefPubMedPubMedCentral Engmann NJ, Golmakani MK, Miglioretti DL et al (2017) Population-attributable risk proportion of clinical risk factors for breast cancer. JAMA Oncol 3(9):1228–1236CrossRefPubMedPubMedCentral
5.
go back to reference Pfeiffer RM, Webb-Vargas Y, Wheeler W, Gail MH (2018) Proportion of U.S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev 27(10):1214–1222CrossRefPubMedPubMedCentral Pfeiffer RM, Webb-Vargas Y, Wheeler W, Gail MH (2018) Proportion of U.S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev 27(10):1214–1222CrossRefPubMedPubMedCentral
6.
go back to reference Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416CrossRefPubMed Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416CrossRefPubMed
8.
go back to reference Sung H, Siegel RL, Torre LA et al (2019) Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin 69(2):88–112PubMed Sung H, Siegel RL, Torre LA et al (2019) Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin 69(2):88–112PubMed
9.
go back to reference Liu N, Johnson KJ, Ma CX (2018) Male breast cancer: an updated surveillance, epidemiology, and end results data analysis. Clin Breast Cancer 18(5):e997–e1002CrossRefPubMed Liu N, Johnson KJ, Ma CX (2018) Male breast cancer: an updated surveillance, epidemiology, and end results data analysis. Clin Breast Cancer 18(5):e997–e1002CrossRefPubMed
10.
go back to reference Korde LA, Zujewski JA, Kamin L et al (2010) Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 28(12):2114–2122CrossRefPubMedPubMedCentral Korde LA, Zujewski JA, Kamin L et al (2010) Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 28(12):2114–2122CrossRefPubMedPubMedCentral
11.
go back to reference Gucalp A, Traina TA, Eisner JR et al (2019) Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat 173(1):37–48CrossRefPubMed Gucalp A, Traina TA, Eisner JR et al (2019) Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat 173(1):37–48CrossRefPubMed
13.
go back to reference GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1789–1858CrossRef GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1789–1858CrossRef
14.
go back to reference Liu Z, Jiang Y, Yuan H et al (2019) The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol 70(4):674–683CrossRefPubMed Liu Z, Jiang Y, Yuan H et al (2019) The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol 70(4):674–683CrossRefPubMed
15.
go back to reference Lin L, Yan L, Liu Y et al (2019) Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study. J Hematol Oncol 12(1):96CrossRefPubMedPubMedCentral Lin L, Yan L, Liu Y et al (2019) Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study. J Hematol Oncol 12(1):96CrossRefPubMedPubMedCentral
17.
go back to reference GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388(10053):1545–1602CrossRef GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388(10053):1545–1602CrossRef
18.
go back to reference GBD 2016 Causes of Death Collaborators (2017) Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(10100):1151–1210CrossRef GBD 2016 Causes of Death Collaborators (2017) Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(10100):1151–1210CrossRef
19.
go back to reference GBD 2017 Causes of Death Collaborators (2018) Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1736–1788CrossRef GBD 2017 Causes of Death Collaborators (2018) Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1736–1788CrossRef
20.
go back to reference Allemani C, Matsuda T, Di Carlo V et al (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391(10125):1023–1075CrossRefPubMedPubMedCentral Allemani C, Matsuda T, Di Carlo V et al (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391(10125):1023–1075CrossRefPubMedPubMedCentral
21.
go back to reference DeSantis CE, Bray F, Ferlay J et al (2015) International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev 24(10):1495–1506CrossRefPubMed DeSantis CE, Bray F, Ferlay J et al (2015) International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev 24(10):1495–1506CrossRefPubMed
22.
go back to reference Youlden DR, Cramb SM, Dunn NA et al (2012) The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 36(3):237–248CrossRefPubMed Youlden DR, Cramb SM, Dunn NA et al (2012) The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 36(3):237–248CrossRefPubMed
25.
go back to reference Jacklyn G, McGeechan K, Irwig L et al (2017) Trends in stage-specific breast cancer incidence in New South Wales, Australia: insights into the effects of 25 years of screening mammography. Breast Cancer Res Treat 166(3):843–854CrossRefPubMed Jacklyn G, McGeechan K, Irwig L et al (2017) Trends in stage-specific breast cancer incidence in New South Wales, Australia: insights into the effects of 25 years of screening mammography. Breast Cancer Res Treat 166(3):843–854CrossRefPubMed
26.
go back to reference Wu WY, Tornberg S, Elfstrom KM et al (2018) Overdiagnosis in the population-based organized breast cancer screening program estimated by a non-homogeneous multi-state model: a cohort study using individual data with long-term follow-up. Breast Cancer Res 20(1):153CrossRefPubMedPubMedCentral Wu WY, Tornberg S, Elfstrom KM et al (2018) Overdiagnosis in the population-based organized breast cancer screening program estimated by a non-homogeneous multi-state model: a cohort study using individual data with long-term follow-up. Breast Cancer Res 20(1):153CrossRefPubMedPubMedCentral
27.
go back to reference Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRefPubMed Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRefPubMed
28.
go back to reference Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674CrossRefPubMed Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674CrossRefPubMed
29.
go back to reference Anderson WF, Reiner AS, Matsuno RK, Pfeiffer RM (2007) Shifting breast cancer trends in the United States. J Clin Oncol 25(25):3923–3929CrossRefPubMed Anderson WF, Reiner AS, Matsuno RK, Pfeiffer RM (2007) Shifting breast cancer trends in the United States. J Clin Oncol 25(25):3923–3929CrossRefPubMed
30.
go back to reference Colditz GA, Bohlke K (2014) Priorities for the primary prevention of breast cancer. CA Cancer J Clin 64(3):186–194CrossRefPubMed Colditz GA, Bohlke K (2014) Priorities for the primary prevention of breast cancer. CA Cancer J Clin 64(3):186–194CrossRefPubMed
31.
go back to reference Collaborative Group on Hormonal Factors in Breast Cancer (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394(10204):1159–1168CrossRefPubMedCentral Collaborative Group on Hormonal Factors in Breast Cancer (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394(10204):1159–1168CrossRefPubMedCentral
32.
go back to reference Poli A, Marangoni F, Visioli F (2012) Alcohol consumption and breast cancer risk. JAMA 307(7):666; author reply 666.CrossRefPubMed Poli A, Marangoni F, Visioli F (2012) Alcohol consumption and breast cancer risk. JAMA 307(7):666; author reply 666.CrossRefPubMed
33.
go back to reference Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ et al (2017) Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention. CA Cancer J Clin 67(5):378–397CrossRefPubMedPubMedCentral Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ et al (2017) Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention. CA Cancer J Clin 67(5):378–397CrossRefPubMedPubMedCentral
34.
go back to reference Lee IM, Shiroma EJ, Lobelo F et al (2012) Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 380(9838):219–229CrossRefPubMedPubMedCentral Lee IM, Shiroma EJ, Lobelo F et al (2012) Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 380(9838):219–229CrossRefPubMedPubMedCentral
35.
go back to reference Beaber EF, Buist DS, Barlow WE et al (2014) Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Res 74(15):4078–4089CrossRefPubMedPubMedCentral Beaber EF, Buist DS, Barlow WE et al (2014) Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Res 74(15):4078–4089CrossRefPubMedPubMedCentral
36.
go back to reference Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97(22):1652–1662CrossRefPubMed Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97(22):1652–1662CrossRefPubMed
37.
go back to reference Goss PE, Ingle JN, Ales-Martinez JE et al (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364(25):2381–2391CrossRefPubMed Goss PE, Ingle JN, Ales-Martinez JE et al (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364(25):2381–2391CrossRefPubMed
38.
go back to reference Tamimi RM, Spiegelman D, Smith-Warner SA et al (2016) Population attributable risk of modifiable and nonmodifiable breast cancer risk factors in postmenopausal breast cancer. Am J Epidemiol 184(12):884–893CrossRefPubMedPubMedCentral Tamimi RM, Spiegelman D, Smith-Warner SA et al (2016) Population attributable risk of modifiable and nonmodifiable breast cancer risk factors in postmenopausal breast cancer. Am J Epidemiol 184(12):884–893CrossRefPubMedPubMedCentral
39.
go back to reference Smith BD, Smith GL, Hurria A et al (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27(17):2758–2765CrossRefPubMed Smith BD, Smith GL, Hurria A et al (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27(17):2758–2765CrossRefPubMed
40.
go back to reference Manthey J, Shield KD, Rylett M et al (2019) Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet 393(10190):2493–2502CrossRefPubMed Manthey J, Shield KD, Rylett M et al (2019) Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet 393(10190):2493–2502CrossRefPubMed
41.
go back to reference Fentiman IS, Fourquet A, Hortobagyi GN (2006) Male breast cancer. The Lancet 367(9510):595–604CrossRef Fentiman IS, Fourquet A, Hortobagyi GN (2006) Male breast cancer. The Lancet 367(9510):595–604CrossRef
42.
43.
go back to reference Talibov M, Hansen J, Heikkinen S et al (2019) Occupational exposures and male breast cancer: A nested case-control study in the Nordic countries. Breast 48:65–72CrossRefPubMed Talibov M, Hansen J, Heikkinen S et al (2019) Occupational exposures and male breast cancer: A nested case-control study in the Nordic countries. Breast 48:65–72CrossRefPubMed
44.
go back to reference Ruddy KJ, Winer EP (2013) Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 24(6):1434–1443CrossRefPubMed Ruddy KJ, Winer EP (2013) Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 24(6):1434–1443CrossRefPubMed
Metadata
Title
Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990–2017
Authors
Zhilin Chen
Lu Xu
Wenjie Shi
Fanyu Zeng
Rui Zhuo
Xinbao Hao
Pingming Fan
Publication date
01-04-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05561-1

Other articles of this Issue 2/2020

Breast Cancer Research and Treatment 2/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine